TITLE

AVIDEX APPOINTS ULTRAFINE TO DEVELOP/MANUFACTURE RHUDEX

PUB. DATE
May 2004
SOURCE
Worldwide Biotech;May2004, Vol. 16 Issue 5, p2
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the decision of Avidex Ltd. to appoint Ultrafine to provide process development and manufacture RhuDex, a CD80 inhibitor. Information on the RhuDex drug; Reason of Avidex for selecting Ultrafine; Background of Ultrafine.
ACCESSION #
13040751

 

Related Articles

  • pharmaceuticals & fine chemicals.  // Chemical Week;3/31/2004, Vol. 166 Issue 11, p43 

    Presents news briefs on contracts in the pharmaceutical and fine chemicals industries as of March 31, 2004. Contract received by pharma intermediates firm Ultrafine from pharma company Avidex; Contract deal between Peakdale Molecular and GlaxoSmithKline.

  • Avidex and Active Biotech to develop anticancer fusion proteins.  // PharmaWatch: Biotechnology;June 2004, Vol. 3 Issue 6, p16 

    Reports on the collaboration between Avidex Ltd. and Active Biotech AB for the development of targeted immunotherapeutics for cancer. Terms of the agreement; Ability of the superantigen to stimulate T cells to kill the target cancer cells; Value of the cancer technology.

  • Two unite on cancer drugs.  // European Chemical News;9/8/2003, Vol. 79 Issue 2067, p28 

    Reports on the partnership of Avidex and Dow Chemical to create biotargeted radio-pharmaceuticals for cancer treatment through the application of Dow technology to Avidex's monoclonal T cell receptors. Terms of the agreement; Implication of the agreement.

  • Ultrafine tunes Arakis deal.  // European Chemical News;11/24/2003, Vol. 79 Issue 2078, p28 

    Reports that fine chemical specialist Ultrafine has expanded an agreement with specialty pharmaceutical company Arakis to provide for early phase guanosine monophosphate manufacturing in 2003.

  • Array's $713M ChK-1 Deal with Genentech Pays Either Way. Morrison, Trista // BioWorld Today;8/10/2011, Vol. 22 Issue 154, p1 

    The article focuses on the agreement signed by Genentech with Array BioPharma Inc. to obtain the rights to the preclinical Ch K-1 inhibitor ARRY-575. Array Chief Executive Officer (CEO) Robert Conway explains the structure of the Genentech-Array deal. It notes the importance of deal-making to...

  • Cobra signs Avidex agreement.  // Pharmaceutical Technology Europe;May2004 Supp, Vol. 16, p8 

    Cobra Biomanufacturing PLC (Keele, Great Britain) and biotech company Avidex Ltd. have announced an agreement for the manufacture of Avidex's lead anticancer product. The programme of work includes process development, production and supply of GMP material through Phase I clinical trials. Cobra...

  • Avidex raises £11.5 million of new funding.  // Pharmaceutical Technology Europe;Nov2002, Vol. 14 Issue 11, p7 

    Reports that Avidex Ltd., a British developer of pharmaceutics, has completed a funding round of 11.5 million pounds in November 2002. Lead investors; Fund allocation.

  • Activation of neurokinin NKreceptors by tachykinin peptides causes contraction of uterus in pregnant women near term. Patak, Eva N.; Ziccone, Sebastian; Story, Margot E. // MHR: Basic Science of Reproductive Medicine;Jun2000, Vol. 6 Issue 6 

    Investigates the activation of neurokinin receptors by tachykinin peptides which causes contraction of uterus in pregnant women near term. Investigation of the receptor subtypes responsible for myometrium contractility; Tachykinin susceptibility to hydrolysis through peptidase inhibitor use;...

  • Pre-signing partnering agreements: Pride, productivity and effort. Ridilla, Paul // Plumbing & Mechanical;May96, Vol. 13 Issue 3, p16 

    Focuses on pre-signing partnership agreements. Use of the Total Quality Management concept; Partnering team roster; Strategy meeting; On-going relationships for future projects.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics